Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) trials share a challenge that’s easy to underestimate, being that much of what they measure depends on subjective reporting. Cognitive change, functional decline, and behavior are all endpoints that often rely on performance and/or observation of the participant and input of a study partner. That reliance opens the door to placebo response, which is more pervasive than trial teams may assume.
Our Clinical Assessment Training and Surveillance (CATS) team set out to quantify just how present that effect is. The results are a useful reminder for anyone designing or running a trial in this space.
What We Looked At
We reviewed 14 multinational, placebo-controlled AD and MCI efficacy studies, covering more than 4,600 participants diagnosed across the spectrum, from MCI to early-stage through severe AD, including participants with clinically significant agitation. Every study required a study partner to support primary and secondary outcomes, using common instruments like the Clinical Dementia Rating Scale, ADCS measures of daily living and global impression of change, as well as the Disability Assessment for Dementia.
We focused specifically on adverse event (AE) reporting between placebo and treatment arms, across categories including gastrointestinal, anorexia, sleep disturbance, and behavioral symptoms.
What We Found
Participants assigned to placebo reported adverse events at rates that didn’t meaningfully differ from those assigned to active treatment. In other words, people who received no active drug still experienced, and reported, side effects at a comparable level to those who did.
Across the studies, this pattern was consistent enough to suggest that expectation itself appears to be shaping how participants and their study partners perceive and report symptoms. That matters because most of these trials also showed mixed results on clinical benefit. When a placebo group shows a similar AE profile to the treatment group, it raises a real question of how much of the outcome signal is being diluted by placebo response, particularly in trials where a clear treatment effect never emerged.
Why This Happens in AD & MCI Trials Specifically
A few things make this patient population especially susceptible:
- Reliance on study partners. Outcome reporting often depends on a caregiver’s or family member’s recall whose own expectations, hopes, and observations shape the data.
- Subjective and effort-dependent assessments. Tools like the ADAS-Cog or MMSE depend on participant engagement and effort, which can vary, based on expectations and rapport with site staff.
- High-touch trial design. Frequent visits, attentive staff, and a structured care environment can themselves produce a therapeutic benefit that has nothing to do with the study drug.
None of this is a flaw in these trials; it’s a structural feature of the disease area. But this is something that trial teams can actively plan around.
What Sponsors & Sites Can Do About It
Our review found that most studies didn’t include explicit strategies to manage placebo response. A few approaches worth building into trial design:
- Participant and study partner education on what placebo and nocebo effects are, set early and reinforced throughout the study
- Staff training focused on managing participant and study partner expectations, not just administering assessments
- Standardized assessment training so scoring and administration stay consistent across sites and raters
- Neutrality in the research environment, keeping the clinical trial visit distinct from a therapeutic one
- Thoughtful visit design, balancing necessary contact with participants against the risk of over-attention driving a therapeutic effect
- Awareness of participant and study partner burden, which can itself influence how symptoms are reported
The Takeaway
Placebo response is a measurable, recurring pattern that can blur the line between a drug that isn’t working and a drug whose signal is being masked. Building placebo mitigation into trial design from the start, through training, education, and a deliberate research environment, gives sponsors a better shot at seeing a compound’s true effect, and a clearer read on whether it’s working.
Want To See the Full Analysis?
This post is drawn from original research presented by our Clinical Assessment Training and Surveillance (CATS) team at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. View the full poster, including the complete data set and statistical findings, here.
Designing an AD or MCI trial and want to talk through placebo mitigation strategies for your protocol? Get in touch with our team.
